Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
The company is eligible for 12 months exclusivity from launch
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Subscribe To Our Newsletter & Stay Updated
